Cargando…

Comparison of the Performance of the PanBio COVID-19 Antigen Test in SARS-CoV-2 B.1.1.7 (Alpha) Variants versus non-B.1.1.7 Variants

This study evaluates the performance of the PanBio COVID-19 antigen (Ag) test as part of a hospital infection control policy. Hospital staff was encouraged to get tested for COVID-19 when presenting with SARS-CoV-2-related symptoms. In a period of approximately 5 months, a steady decline in the perf...

Descripción completa

Detalles Bibliográficos
Autores principales: van Ogtrop, M. L., van de Laar, T. J. W., Eggink, D., Vanhommerig, J. W., van der Reijden, W. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612141/
https://www.ncbi.nlm.nih.gov/pubmed/34817226
http://dx.doi.org/10.1128/Spectrum.00884-21
_version_ 1784603419841921024
author van Ogtrop, M. L.
van de Laar, T. J. W.
Eggink, D.
Vanhommerig, J. W.
van der Reijden, W. A.
author_facet van Ogtrop, M. L.
van de Laar, T. J. W.
Eggink, D.
Vanhommerig, J. W.
van der Reijden, W. A.
author_sort van Ogtrop, M. L.
collection PubMed
description This study evaluates the performance of the PanBio COVID-19 antigen (Ag) test as part of a hospital infection control policy. Hospital staff was encouraged to get tested for COVID-19 when presenting with SARS-CoV-2-related symptoms. In a period of approximately 5 months, a steady decline in the performance of the Ag test was noted, epidemiologically coinciding with the rise of the SARS-CoV-2 B.1.1.7 (alpha) variant of concern (VOC) in the Netherlands. This led to the hypothesis that the diagnostic performance of the PanBio COVID-19 Ag test was influenced by the infecting viral variant. The results show a significantly lower sensitivity of the PanBio COVID-19 Ag test in persons infected with the B.1.1.7 (alpha) variant of SARS-CoV-2 in comparison with that in persons infected with non-B.1.1.7 variants, also after adjustment for viral load. IMPORTANCE Antigen tests for COVID-19 are widely used for rapid identification of COVID-19 cases, for example, for access to schools, festivals, and travel. There are several FDA- and CE-cleared tests on the market. Their performance has been evaluated mainly on the basis of infections by the classical variant of the causing virus, SARS-CoV-2. This paper provides evidence that the performance of one of the most widely used antigen tests detects significantly fewer cases of COVID-19 by the alpha variant than by the classical variants of SARS-CoV-2. This means that the role of antigen tests needs to be reevaluated in regions where other variants of SARS-CoV-2 predominate.
format Online
Article
Text
id pubmed-8612141
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-86121412021-11-29 Comparison of the Performance of the PanBio COVID-19 Antigen Test in SARS-CoV-2 B.1.1.7 (Alpha) Variants versus non-B.1.1.7 Variants van Ogtrop, M. L. van de Laar, T. J. W. Eggink, D. Vanhommerig, J. W. van der Reijden, W. A. Microbiol Spectr Research Article This study evaluates the performance of the PanBio COVID-19 antigen (Ag) test as part of a hospital infection control policy. Hospital staff was encouraged to get tested for COVID-19 when presenting with SARS-CoV-2-related symptoms. In a period of approximately 5 months, a steady decline in the performance of the Ag test was noted, epidemiologically coinciding with the rise of the SARS-CoV-2 B.1.1.7 (alpha) variant of concern (VOC) in the Netherlands. This led to the hypothesis that the diagnostic performance of the PanBio COVID-19 Ag test was influenced by the infecting viral variant. The results show a significantly lower sensitivity of the PanBio COVID-19 Ag test in persons infected with the B.1.1.7 (alpha) variant of SARS-CoV-2 in comparison with that in persons infected with non-B.1.1.7 variants, also after adjustment for viral load. IMPORTANCE Antigen tests for COVID-19 are widely used for rapid identification of COVID-19 cases, for example, for access to schools, festivals, and travel. There are several FDA- and CE-cleared tests on the market. Their performance has been evaluated mainly on the basis of infections by the classical variant of the causing virus, SARS-CoV-2. This paper provides evidence that the performance of one of the most widely used antigen tests detects significantly fewer cases of COVID-19 by the alpha variant than by the classical variants of SARS-CoV-2. This means that the role of antigen tests needs to be reevaluated in regions where other variants of SARS-CoV-2 predominate. American Society for Microbiology 2021-11-24 /pmc/articles/PMC8612141/ /pubmed/34817226 http://dx.doi.org/10.1128/Spectrum.00884-21 Text en Copyright © 2021 van Ogtrop et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
van Ogtrop, M. L.
van de Laar, T. J. W.
Eggink, D.
Vanhommerig, J. W.
van der Reijden, W. A.
Comparison of the Performance of the PanBio COVID-19 Antigen Test in SARS-CoV-2 B.1.1.7 (Alpha) Variants versus non-B.1.1.7 Variants
title Comparison of the Performance of the PanBio COVID-19 Antigen Test in SARS-CoV-2 B.1.1.7 (Alpha) Variants versus non-B.1.1.7 Variants
title_full Comparison of the Performance of the PanBio COVID-19 Antigen Test in SARS-CoV-2 B.1.1.7 (Alpha) Variants versus non-B.1.1.7 Variants
title_fullStr Comparison of the Performance of the PanBio COVID-19 Antigen Test in SARS-CoV-2 B.1.1.7 (Alpha) Variants versus non-B.1.1.7 Variants
title_full_unstemmed Comparison of the Performance of the PanBio COVID-19 Antigen Test in SARS-CoV-2 B.1.1.7 (Alpha) Variants versus non-B.1.1.7 Variants
title_short Comparison of the Performance of the PanBio COVID-19 Antigen Test in SARS-CoV-2 B.1.1.7 (Alpha) Variants versus non-B.1.1.7 Variants
title_sort comparison of the performance of the panbio covid-19 antigen test in sars-cov-2 b.1.1.7 (alpha) variants versus non-b.1.1.7 variants
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612141/
https://www.ncbi.nlm.nih.gov/pubmed/34817226
http://dx.doi.org/10.1128/Spectrum.00884-21
work_keys_str_mv AT vanogtropml comparisonoftheperformanceofthepanbiocovid19antigentestinsarscov2b117alphavariantsversusnonb117variants
AT vandelaartjw comparisonoftheperformanceofthepanbiocovid19antigentestinsarscov2b117alphavariantsversusnonb117variants
AT egginkd comparisonoftheperformanceofthepanbiocovid19antigentestinsarscov2b117alphavariantsversusnonb117variants
AT vanhommerigjw comparisonoftheperformanceofthepanbiocovid19antigentestinsarscov2b117alphavariantsversusnonb117variants
AT vanderreijdenwa comparisonoftheperformanceofthepanbiocovid19antigentestinsarscov2b117alphavariantsversusnonb117variants